MNOV - MediciNova, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.0600
-0.3000 (-8.93%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.3600
Open3.3300
Bid2.9700 x 800
Ask4.6300 x 900
Day's Range3.0300 - 3.3300
52 Week Range2.7900 - 13.3700
Volume115,095
Avg. Volume116,298
Market Cap134.505M
Beta (5Y Monthly)1.64
PE Ratio (TTM)N/A
EPS (TTM)-0.3000
Earnings DateApr 22, 2020 - Apr 26, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.50
  • MNOV: MN-166 to be Developed as a Treatment for Severe Pneumonia and Acute Respiratory Distress Syndrome…
    Zacks Small Cap Research

    MNOV: MN-166 to be Developed as a Treatment for Severe Pneumonia and Acute Respiratory Distress Syndrome…

    By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update MN-166 to be Developed for Severe Pneumonia and ARDS On March 9, 2020, MediciNova, Inc. (NASDAQ:MNOV) announced that based upon preclinical results that were recently published the company will develop MN-166 (ibudilast) as a treatment for severe pneumonia and acute respiratory distress syndrome (ARDS). ARDS

  • GlobeNewswire

    MediciNova Announces Plans to Develop MN-166 (ibudilast) for Severe Pneumonia and Acute Respiratory Distress Syndrome (ARDS)

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans to initiate development of MN-166 (ibudilast) for severe pneumonia and acute respiratory distress syndrome (ARDS). MediciNova’s decision to pursue development of this indication was based on positive results of a recent preclinical study in an animal model of ARDS (Med Sci Monit, 2020; 26: e922281).

  • Should You Be Concerned About MediciNova, Inc.'s (NASDAQ:MNOV) Historical Volatility?
    Simply Wall St.

    Should You Be Concerned About MediciNova, Inc.'s (NASDAQ:MNOV) Historical Volatility?

    If you own shares in MediciNova, Inc. (NASDAQ:MNOV) then it's worth thinking about how it contributes to the...

  • MNOV: Multiple Trials of MN-166 Ongoing; Recent Price Move Creates Buying Opportunity
    Zacks Small Cap Research

    MNOV: Multiple Trials of MN-166 Ongoing; Recent Price Move Creates Buying Opportunity

    By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Financial Update On February 13, 2020, MediciNova (NASDAQ:MNOV) filed Form 10-K with financial results for the full year 2019. As expected, the company did not report any revenues. Net loss for 2019 was $12.9 million, or $0.30 per share, compared to a net loss of $14.7 million, or $0.36 per share, in 2018. The $12.9 million net

  • GlobeNewswire

    MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Japan

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of advanced nonalcoholic steatohepatitis (NASH). Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than May 2035. The allowed claims also cover advanced NASH patients that exhibit hepatic fibrosis, spider angiomata, ascites, splenomegaly, hard liver border, palmar erythema, asterixis, portal hypertension, hepatic scarring, cirrhosis, or hepatocellular carcinoma (HCC).

  • Benzinga

    The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 27) 10X Genomics Inc (NASDAQ: TXG ) Achillion Pharmaceuticals, ...

  • GlobeNewswire

    MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in Europe

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-001 (tipelukast) for the treatment of idiopathic pulmonary fibrosis (IPF). Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than May 2035. The allowed claims cover the use of MN-001 for treating a patient diagnosed with idiopathic pulmonary fibrosis.

  • GlobeNewswire

    MediciNova Announces Additional Analyses from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 30th International Symposium on ALS/MND in Perth, Australia

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that additional analyses of MediciNova’s completed clinical trial of MN-166 (ibudilast) in ALS (amyotrophic lateral sclerosis), which was conducted at Carolinas HealthCare System’s Neuromuscular/ALS-MDA Center at Carolinas HealthCare System Neurosciences Institute, will be presented on December 5, 2019 at 10:30 am local time at the 30th International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease) in Perth, Australia.

  • We're Not Worried About MediciNova's (NASDAQ:MNOV) Cash Burn
    Simply Wall St.

    We're Not Worried About MediciNova's (NASDAQ:MNOV) Cash Burn

    Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

  • Here is What Hedge Funds Think About MediciNova, Inc. (MNOV)
    Insider Monkey

    Here is What Hedge Funds Think About MediciNova, Inc. (MNOV)

    Is MediciNova, Inc. (NASDAQ:MNOV) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting […]

  • MNOV: Phase 3 Trial Initiated for MN-166 in ALS
    Zacks Small Cap Research

    MNOV: Phase 3 Trial Initiated for MN-166 in ALS

    By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT HERE Business Update Phase 3 Trial of MN-166 in ALS Underway In April 2019, MediciNova, Inc. (NASDAQ:MNOV) announced that following review of the protocol the U.S. Food and Drug Administration (FDA) determined that the company may proceed with the Phase 2b/3 clinical trial of MN-166 (ibudilast) in amyotrophic lateral

  • GlobeNewswire

    MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of amyotrophic lateral sclerosis (ALS). The allowed claims cover the use of MN-166 (ibudilast) to treat a patient diagnosed with ALS.  The allowed claims cover oral administration in a wide range of daily dosages.  Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2028.

  • GlobeNewswire

    MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of NAFLD and NASH in Japan

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-001 (tipelukast) for the treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

  • GlobeNewswire

    MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Idiopathic Pulmonary Fibrosis in Japan

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of idiopathic pulmonary fibrosis (IPF).

  • GlobeNewswire

    MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in China

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Chinese Patent Office for a pending patent application which covers MN-001 (tipelukast) for the treatment of idiopathic pulmonary fibrosis (IPF).

  • Does Market Volatility Impact MediciNova, Inc.'s (NASDAQ:MNOV) Share Price?
    Simply Wall St.

    Does Market Volatility Impact MediciNova, Inc.'s (NASDAQ:MNOV) Share Price?

    Anyone researching MediciNova, Inc. (NASDAQ:MNOV) might want to consider the historical volatility of the share price...

  • GlobeNewswire

    MediciNova to Present at the Ladenburg Thalmann 2019 Healthcare Conference in New York

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O'Brien, JD/MBA, Vice President and Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019 at 10:30 am at the Sofitel Hotel in New York City.  Management will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through Ladenburg Thalmann. MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S. market.

  • GlobeNewswire

    MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New York

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will attend the Morgan Stanley Global Healthcare Conference which will be held at the Grand Hyatt New York in New York City from September 9 - 11, 2019. Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through Morgan Stanley. MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S. market.

  • Zacks Small Cap Research

    MNOV: Abstract on MN-166 to be Presented at ALS/MND International Symposium…

    On July 25, 2019, MediciNova, Inc. (MNOV) filed form 10-Q with financial results for the second quarter of 2019. The increase was due to higher stock-based compensation offset by lower clinical trial expenses. As of July 24, 2019, MediciNova had approximately 43.2 million shares of common stock outstanding and when factoring in the approximately 6.8 million stock options a fully diluted share count of 50.1 million.

  • GlobeNewswire

    MediciNova Announces MN-001 Research Collaboration with the National Cerebral and Cardiovascular Disease Research Center in Japan

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will initiate a comprehensive research collaboration with the Japanese National Cerebral and Cardiovascular Disease Research Center,  Division of Lipid Metabolism, Department of Molecular Innovation in Lipidology, to evaluate the effects of MN-001 (tipelukast) on lipid metabolism and metabolic syndrome. Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of MediciNova, Inc., commented, “MN‑001 is a novel orally-administered compound with multiple mechanisms, and its anti-fibrosis and anti-inflammatory effects have been observed in multiple animal models studies.

  • GlobeNewswire

    MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 30th International Symposium on ALS/MND in Perth, Australia

    The presentation entitled "Interaction (nonuniformity) of ALS Progression and the Efficacy of MN‑166 (ibudilast)” will be given by Kazuko Matsuda, M.D. Ph.D. M.P.H., Chief Medical Officer, MediciNova, Inc. Presentation details will be disseminated as they become available. “We are very pleased to present additional findings from the completed ALS study at the 30th International Symposium on ALS/MND.

  • GlobeNewswire

    MediciNova Appoints Kazuko Matsuda to its Board of Directors

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the appointment of Dr. Kazuko Matsuda to its Board of Directors. Dr. Matsuda received her M.D. and Ph.D. from Sapporo Medical School in Japan, and Master of Public Health from Harvard University, School of Public Health, in the U.S. She is a board-certified pediatrician in both the United States and Japan. Dr. Matsuda, in her capacity as Chief Medical Officer for MediciNova since 2013, has demonstrated time and again strong leadership skills and creativity culminating in the advancement of MediciNova’s promising clinical drug development programs.

  • Zacks Small Cap Research

    MNOV: Readying for Phase 3 Trial in Multiple Sclerosis…

    The company is planning to conduct a single Phase 3 trial in patients with secondary progressive MS (SPMS) without relapses with the primary endpoint being the time to 3-month confirmed disability progression as measured by Expanded Disability Status Scale (EDSS). The EDSS is the ‘gold standard’ for assessing disability progression in patients with MS (Kurtzke, 1983).

  • What Type Of Shareholder Owns MediciNova, Inc.'s (NASDAQ:MNOV)?
    Simply Wall St.

    What Type Of Shareholder Owns MediciNova, Inc.'s (NASDAQ:MNOV)?

    If you want to know who really controls MediciNova, Inc. (NASDAQ:MNOV), then you'll have to look at the makeup of its...

  • GlobeNewswire

    MediciNova Announces Phase 3 Clinical Trial Plan for MN-166 (ibudilast) in Progressive MS

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced its plans for a Phase 3 clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS) following feedback from the FDA (U.S. Food and Drug Administration).